ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
avoided, the dose of pirfenidone should be reduced to 1602 mg daily (two capsules, three times a day) Esbriet should be used with caution when ciprofloxacin is used at a dose of 250 mg or 500mg once or two times a day Esbriet should be used with caution in patients treated with other moderate inhibitors of CYP1A2 (e g amiodarone, propafenone)
Esbriet - European Medicines Agency
Esbriet pirfenidone On 16 December 2010 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Esbriet, hard capsules, 267 mg intended for treatment of idiopathic pulmonary fibrosis (IPF) Esbriet was
Fewer pills, more flexibility in dosing: Roche’s new Esbriet
Jun 27, 2017 · Esbriet is conditionally recommended for use in people with IPF in the ATS / ERS / JRS / ALAT treatment guidelines published in July 2015 18 Pirfenidone has been marketed as Pirespa since 2008 in Japan and since 2012 in South Korea by Shionogi & Co Ltd Under different trade names, pirfenidone is also approved for the
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Esbriet 267 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 267 mg pirfenidone For a full list of excipients, see section 6 1 3 PHARMACEUTICAL FORM Hard capsule (capsule) Two piece capsules with a blue opaque body and gold opaque cap imprinted with “InterMune 267 mg”
Results of a six-month study combining Roche’s Esbriet with
Sep 13, 2017 · Esbriet is conditionally recommended for use in people with IPF in the ATS / ERS / JRS / ALAT treatment guidelines published in July 2015 13 Pirfenidone has been marketed as Pirespa since 2008 in Japan and since 2012 in South Korea by Shionogi & Co Ltd Under different trade names, pirfenidone is also approved for the
I PIELIKUMS ZĀĻU APRAKSTS - European Commission
Esbriet 267 mg cietās kapsulas 2 KVALITATĪVAIS UN KVANTITATĪVAIS SASTĀVS Katra kapsula satur 267 mg pirfenidona (pirfenidone) Pilnu palīgvielu sarakstu skatīt 6 1 apakšpunktā 3 ZĀĻU FORMA Cietā kapsula (kapsula) Divdaļīgas kapsulas ar baltu necaurspīdīgu korpusu un baltu necaurspīdīgu vāciņu ar brūnu uzrakstu
List of medicinal products under additonal monitoring
http://www ema europa eu/ema/index jsp?curl=pages/medicines/human/me dicines/002455/human_med_001588 jsp&mid=WC0b01ac058001d124 Aldurazyme
[PDF] LES ESCALIERS
[PDF] E coli - Anses
[PDF] 19 La traite des esclaves - Académie de Nancy-Metz
[PDF] L 'escompte Les moyens de paiement concernés L 'escompte
[PDF] l 'Escompte - Marketing Thus
[PDF] l 'Escompte - Marketing Thus
[PDF] mastère spécialisé marketing et communication - Top Universities
[PDF] BASES DE L 'ESCRIME A L 'EPEE LONGUE DE - WordPresscom
[PDF] Dossier escrime 1
[PDF] TALLERES PARA PADRES DE FAMILIA Taller N° 1 Familia y
[PDF] Manual didáctico para la Escuela de Padres - Centro de Solidaridad
[PDF] Manual didáctico para la Escuela de Padres - Centro de Solidaridad
[PDF] FUNCIONALISMO: Características principales: Principales
[PDF] cuadro sinóptico de las diferentes escuelas psicológicas